News

The community of microbes in the gut, called the gut microbiome, was affected by age, antibiotic use, and geography among infants with cystic fibrosis (CF) in the U.S. and Australia, according to a new study in the two nations. Babies with CF in Australia, where preventive antibiotic usage is…

As more adults with cystic fibrosis (CF) choose to become parents, they face unique challenges in balancing the responsibilities of caring for their children and managing their disease, a study highlights. Researchers outlined several areas where care teams could be of help, such as working with prospective parents to…

More than half of the cystic fibrosis (CF) patients who may have been eligible for a second lung transplant died while on a waitlist or had no record of being placed on one, according to a recent analysis in the U.S. and Canada. Among those who did have a…

A three-dimensional MRI scan of the lungs can be used to monitor responses by cystic fibrosis (CF) patients to the approved CF medication Trikafta (elexacaftor/tezacaftor/ivacaftor), a new study reports. Indeed, the new 3D technology was found to work better than traditional two-dimensional MRI scans in assessing the effects of Trikafta…

Gene therapy to deliver a modified and better working version of the CFTR protein may be more effective in treating cystic fibrosis (CF) than a gene therapy aiming to deliver higher levels of the protein, a study shows. “Gene therapy and gene editing techniques, whilst still in their infancy,…

Porosome Therapeutics is seeking a U.S. patent that would cover its “radically new and distinctive” technology platform for the treatment of cystic fibrosis (CF) and other health conditions, the company said in a press release. Its platform works by targeting a cellular structure called the porosome. The global…

Bacteriophage therapy could be a promising approach for treating antibiotic-resistant Staphylococcus aureus and Pseudomonas aeruginosa infections in people with cystic fibrosis (CF), according to a small review study. Scientists believe the review, involving three CF patients and two animal models, support moving forward with clinical trials for bacteriophage…

Taking Orkambi (lumacaftor/ivacaftor) for more than two years helped clear trapped air from the lungs of children with cystic fibrosis (CF), ages 6-11, but didn’t prevent an abnormal widening of the airways, a real-world study finds. The findings indicate the medication may not completely stop lung damage from…

Treatment with Kaftrio, a triple combo of elexacaftor, tezacaftor, and ivacaftor sold as Trikafta in the U.S., may help reduce the number of medications people with cystic fibrosis (CF) take each day, a study found. Patients may have to take multiple medications to manage all symptoms of…

Both genetics and environmental factors, such as attending daycare, family income, and maternal education, may determine how early some lung problems develop in children with cystic fibrosis (CF), a study finds. This is important because while variations in a person’s genes can’t be modified, “some extrinsic exposures can and…